HIVE vs OPY

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 12, 2026

HIVE

48.3
AI Score
VS
HIVE Wins

OPY

38.2
AI Score

Investment Advisor Scores

HIVE

48score
Recommendation
HOLD

OPY

38score
Recommendation
SELL

AI Analyst Insights

Detailed Metrics Comparison

Metric HIVE OPY Winner
Forward P/E 62.8931 10.8108 OPY
PEG Ratio 0 12 Tie
Revenue Growth 73.5% 24.1% HIVE
Earnings Growth -99.9% 24.6% OPY
Tradestie Score 48.3/100 38.2/100 HIVE
Profit Margin -98.5% 6.0% OPY
Beta 1.00 1.00 Tie
AI Recommendation HOLD SELL HIVE

Relative Price Performance (Last 90 Days)

HIVE 1M: +10.6% · 3M: -20.1% OPY 1M: +7.4% · 3M: +21.9%

Current Technical Phase

HIVE

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 52

RSI (14): 51.8 · Price: $3.03

OPY

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (5.4% over 20 days), RSI 62

RSI (14): 61.7 · Price: $123.29

Fundamentals Snapshot

Metric HIVE OPY
Market Cap
Forward P/E -5.9 10.8
Trailing P/E 13.6
Revenue (TTM)
Revenue Growth 0.7% 0.2%
Gross Margin 0.4% 0.9%
Operating Margin -0.6% 0.2%
EPS -1.33 9.09
Dividend Yield 0.01%

Frequently Asked Questions

Based on our detailed analysis, HIVE is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.